Spectral AI, Inc. (MDAI) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Spectral AI (MDAI) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Spectral AI is a medical-technology company whose DeepView System combines multispectral imaging with a proprietary AI algorithm to predict the healing potential of burns and wounds at the point of care, helping clinicians decide which tissue will heal and which needs surgery. The thesis is that AI-driven wound assessment can replace subjective visual judgment in burn centers, trauma units, and emergency departments. The biggest risks are blunt: Spectral AI is essentially pre-commercial, its revenue has come almost entirely from government research contracts rather than product sales, it burns cash and remains unprofitable, and any equity holding is highly speculative. As of October 16, 2026 the stock closed near $1.52, up about 5% in 2026 but down about 38% over one year, for a market value of roughly $49 million.

MDAI stock price

As of 2026-11-16, Spectral AI, Inc. (MDAI) last closed at $1.31, down 9.0% over the past year. Over the past 52 weeks it has traded between $1.20 and $2.68.

MDAI last close
$1.31
1 day
+0.77%
1 month
-13.25%
1 year
-9.03%
52-week range
$1.20 to $2.68
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Spectral AI, Inc.'s investor relations page. Walnut is informational, not investment advice.

MDAI key stats

At $1.31 on November 16, 2026, Spectral AI, Inc. (MDAI) has a market cap of $42M.

Market cap
$42M
Beta
1.25

Market cap, P/E and yield are measured at the $1.31 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Spectral AI, Inc. (MDAI)?

The last two weeks for Spectral AI, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MDAI closed at $1.31 on November 16, 2026, down 14.4% over the past five trading days (from $1.53).
  • On November 16, 2026, Spectral AI, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Spectral AI, Inc. (MDAI) do?

Spectral AI, Inc. (NASDAQ: MDAI), based in Dallas, Texas, is an artificial-intelligence medical-technology company focused on wound care. Its flagship DeepView System uses multispectral imaging and a proprietary deep-learning algorithm to assess the healing potential of burns and other wounds, delivering an AI-driven tissue classification in roughly 20 to 25 seconds after a sub-second image capture, without touching the patient. The algorithm was trained and validated on a large proprietary database of clinically labeled burn-wound images. The goal is to give clinicians in burn centers, trauma centers, and emergency departments an objective read on which tissue will heal on its own and which requires surgical intervention, a judgment that has traditionally relied on subjective visual inspection.

Spectral AI became a public company in 2023 via a SPAC merger and has been development-stage for essentially its entire history. Since 2013 it has been awarded roughly $282.5 million in government funding, the large majority from BARDA (the U.S. Biomedical Advanced Research and Development Authority) under a Project BioShield contract valued up to $150 million, with additional U.S. Department of Defense funding supporting a handheld Snapshot module. That government money, booked as research-and-development revenue, has funded most of the company's work. On the regulatory path, Spectral AI submitted a De Novo application to the FDA in June 2025 and received FDA De Novo clearance for the DeepView System's burn indication in May 2026, authorizing U.S. commercial distribution. The financial reality remains stark: full-year 2025 R&D revenue was about $19.7 million (down from $29.6 million) with a net loss of roughly $7.6 million, cash was about $15.4 million at year-end 2025, around $11.7 million by March 31, 2026 and about $14.0 million by June 30, 2026, and the company has relied on equity, warrants, and debt to fund operations as it shifts toward commercialization.

Since clearance the company has moved into the reimbursement and label-expansion phase. Second-quarter 2026 revenue was about $3.5 million, down roughly 30% from $5.1 million a year earlier, with a net loss near $4.2 million and EPS of -$0.13 against a -$0.14 consensus. In October 2026 Spectral AI submitted a New Technology Add-On Payment (NTAP) application for DeepView, a Medicare reimbursement step for new inpatient technology, and announced the first site initiation for a clinical study supporting expansion of the label to burns of the head, hands, and feet. Third-quarter results are expected on November 10, 2026.

What's driving Spectral AI, Inc. (MDAI)?

1. FDA clearance opens the U.S. market.

In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. Clearance authorizes commercial distribution in the United States and is the gate to any meaningful product revenue. Management has signaled it hopes to begin commercializing DeepView by the end of 2026 and is working with Deloitte Consulting on its go-to-market strategy. The opportunity now shifts from getting approved to actually selling and getting reimbursed. On October 6, 2026 the company submitted an NTAP application, which, if granted, would let hospitals receive an add-on Medicare payment when DeepView is used for inpatients, and DeepView was showcased at the American College of Emergency Physicians assembly in October.

2. Non-dilutive government funding.

Spectral AI's development has been financed largely by government contracts, with roughly $282.5 million awarded since 2013, the bulk from BARDA. The company highlighted $31.7 million in advanced, non-dilutive BARDA funding tied to an accelerated phase of its Project BioShield contract, plus DoD support for a handheld module. This funding has let it build the technology with far less shareholder dilution than a typical pre-revenue device company, though it also means most reported revenue is reimbursed research cost, not commercial sales.

3. Large clinical and addressable need.

Assessing burn depth and wound healing is notoriously subjective, and accurate early triage can change whether a patient needs surgery. DeepView aims to standardize that judgment with an objective AI read at the bedside. Beyond initial burn use in burn, trauma, and emergency settings, the company has discussed extending the platform to chronic wounds such as diabetic foot ulcers, a far larger long-term market if the technology proves out and earns its own clearances. The first concrete step past the initial label came in October 2026, with the first site initiation visit for a clinical study supporting expansion to burns of the head, hands, and feet.

4. Commercial build-out underway.

With clearance in hand, Spectral AI is assembling commercial infrastructure: it has been searching for a chief commercial officer, engaged outside consultants on launch strategy, and continued developing a more portable Snapshot module funded by the DoD. Whether these steps convert into installed systems, recurring usage, and reimbursement is the central unknown. Management has guided that 2026 revenue stays roughly flat at about $18.5 million, mostly BARDA-funded, and analyst consensus matches that at about $18.5 million, rising to about $32.4 million in 2027, the year framed as the start of growth. Trailing revenue was about $15.4 million as of mid-2026, so the second half has to be stronger than the first to meet the guide.

What are the risks to Spectral AI, Inc. (MDAI)?

The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with about $14.0 million of cash at June 30, 2026 against roughly $16.3 million of debt and a trailing net loss near $10.1 million, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 32 million shares and a market value near $49 million as of October 16, 2026, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment. The shares are down about 38% over the past year despite the FDA clearance, a sign that the market is waiting for first sales rather than paying for the milestone.

What is the Spectral AI, Inc. (MDAI) forecast?

3 analysts publish price targets on MDAI, averaging $5.11 as of November 2026, or +290.1% against the $1.31 share price on November 16, 2026. The published targets run from $4.00 to $6.25, a moderate spread, and the ratings split 1 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MDAI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is MDAI a buy or a sell?

We give no verdict on Spectral AI, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. FDA clearance opens the U.S. market. In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. The most optimistic published target, $6.25, assumes this works close to its best case.

The case against. The risks are substantial and concentrated. The most pessimistic target, $4.00, is roughly what MDAI is worth if this bites instead.

Read the full bull and bear case on MDAI, including what would have to change to break either one. Walnut is not an investment adviser.

Has Spectral AI, Inc. (MDAI) split its stock?

No. Spectral AI, Inc. (MDAI) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Spectral AI, Inc. (MDAI) valued?

Market cap, P/E and dividend yield at today's price are in the MDAI key stats above. The business figures below come from Spectral AI, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM, mostly research/BARDA): ~$15.4 million; FY2025 was ~$19.7 million
  • Revenue (Q2 2026): ~$3.5 million, down ~30% year over year
  • Net loss (Q2 2026): ~$4.2 million (EPS -$0.13 vs -$0.14 expected)
  • Net loss (TTM): ~$10.1 million
  • Cash / debt: ~$14.0 million cash vs ~$16.3 million debt at Jun 30, 2026

As of October 2026: Spectral AI should be read as a pre-commercial, development-stage company rather than a normal operating business. Almost all of its reported revenue is research-and-development funding reimbursed under government contracts, chiefly BARDA, so the top line reflects grant-funded development rather than product sales, and it fell again in Q2 2026 as a contract phase wound down. Earnings are negative, so a P/E ratio is not meaningful; at about 3x trailing sales the roughly $49 million market cap reflects expectations for commercializing DeepView, not current profits. All figures are approximate as of October 2026 and change each quarter; verify against Spectral AI's investor relations page or your broker.

Who competes with Spectral AI, Inc. (MDAI)?

Wound and burn imaging peers

Spectral AI's most direct competition is other approaches to assessing burns and wounds, including laser doppler imaging systems and other tissue-perfusion and wound-measurement devices, plus the long-standing default of subjective clinical visual assessment. DeepView's differentiation is a non-contact multispectral image plus an AI prediction of healing potential delivered in seconds, but it must displace entrenched methods to win adoption.

Broader AI medical imaging and diagnostics

More broadly, Spectral AI sits in the fast-growing field of AI-assisted medical imaging and diagnostics, where many specialized startups and larger imaging and device companies are applying machine learning to radiology, pathology, dermatology, and surgical guidance. These firms generally target different conditions, but they compete for hospital budgets, clinician attention, and the regulatory and reimbursement pathways that any AI diagnostic must clear.

ETFs and alternatives

Investors seeking exposure to AI in healthcare more broadly often use healthcare, medical-device, or AI-themed ETFs rather than a single micro-cap. As a very small company, MDAI is rarely a meaningful holding in major ETFs and, when present, sits at a tiny weight in small-cap or thematic funds. Holdings shift as funds rebalance, so check a specific ETF's current holdings with its provider; buying the stock directly gives the most concentrated exposure to Spectral AI's specific thesis.

What stocks are similar to Spectral AI, Inc. (MDAI)?

Other names that sit close to MDAI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Spectral AI, Inc. (MDAI)

There are three common ways to get MDAI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MDAI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MDAI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Spectral AI, Inc. (MDAI)

Spectral AI is a way to express the view that AI plus multispectral imaging will become a standard tool for assessing burns and wounds, now that its DeepView System has FDA De Novo clearance for the burn indication. It behaves like a speculative, pre-commercial medical-AI micro-cap: tiny, volatile, funded largely by government contracts, and dependent on turning regulatory progress into actual product sales.

More on Spectral AI, Inc. (MDAI)

Whether MDAI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MDAI a buy or a sell?, and where the stock could go from here in the MDAI stock forecast.

For income investors, whether MDAI pays a dividend and how the payout looks is covered in does MDAI pay a dividend? And to weigh MDAI against a peer, read the full side-by-side comparisons: MDAI vs HNGE and MDAI vs BMY.

Wondering how MDAI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Spectral AI, Inc.

Ask Walnut's AI anything about MDAI and see how it fits what you own.

FAQ

What does Spectral AI do?

+

Spectral AI is a medical-technology company whose DeepView System uses multispectral imaging and a proprietary AI algorithm to assess the healing potential of burns and wounds. It produces an objective, non-contact tissue classification in roughly 20 to 25 seconds, intended to help clinicians in burn centers, trauma centers, and emergency departments decide which tissue will heal on its own and which needs surgery. The company has been funded largely by U.S. government research contracts.

What is DeepView?

+

DeepView is Spectral AI's flagship system. It captures a sub-second multispectral image of a wound and runs a deep-learning algorithm, trained on a large proprietary database of clinically labeled burn images, to predict healing potential without touching the patient. The output aims to replace subjective visual judgment of burn depth with an objective, AI-driven read. A handheld Snapshot version is also in development with U.S. Department of Defense funding.

What is MDAI's FDA status and how is it funded?

+

Spectral AI submitted a De Novo application to the FDA in June 2025 and received FDA De Novo clearance for the DeepView System's burn indication in May 2026, authorizing U.S. commercial distribution. Its development has been funded largely by government contracts, around $282.5 million awarded since 2013, mostly from BARDA under a Project BioShield contract, plus DoD support. That funding is booked as research revenue, so most of the company's reported revenue has come from grants rather than product sales. In October 2026 it filed for a Medicare New Technology Add-On Payment and began a study to expand the label to burns of the head, hands, and feet.

How did Spectral AI do in its latest quarter?

+

For the quarter ended June 30, 2026, Spectral AI reported revenue of about $3.5 million, down roughly 30% from about $5.1 million a year earlier as BARDA work shifted phases, and a net loss of about $4.2 million. EPS of -$0.13 was a cent better than the -$0.14 consensus. Third-quarter results are expected around November 10, 2026, with consensus revenue near $5.3 million.

How has MDAI stock performed in 2026?

+

As of October 16, 2026, MDAI closed near $1.52, up about 4.8% year to date but down about 38% over one year, with a 52-week range of roughly $1.18 to $2.97. The market value is about $49 million. Three analysts carry a mean target near $5.11, far above the share price, which is common for thinly covered micro-caps.

Does MDAI pay a dividend?

+

No. Spectral AI does not pay a dividend, so its yield is 0%. As a pre-commercial, unprofitable company that burns cash and reinvests in development and commercialization, it is not an income stock; any return would come from share-price changes rather than dividends. This is current as of the dates noted; verify against Spectral AI's investor relations page.

Is MDAI a good stock?

+

This is descriptive, not advice. The bull case is that DeepView now has FDA clearance for burns, addresses a real clinical need, and has been built largely with non-dilutive government funding. The bear case is that Spectral AI is highly speculative: essentially pre-commercial, unprofitable, dependent on government contracts for most revenue, low on cash, and likely to dilute shareholders, with commercial adoption still unproven. Whether it fits depends on your own goals and risk tolerance.

Is MDAI a good stock to buy right now?

+

This is informational, not a recommendation. Spectral AI is a speculative micro-cap whose value hinges on turning its new FDA clearance into actual product sales and reimbursement, against a backdrop of cash burn, government-funding dependence, and a small, volatile share count. Some investors find that risk-reward appealing as a tiny position; others avoid pre-commercial stories entirely. Walnut provides information, not investment advice.

Why is MDAI considered speculative?

+

Spectral AI has almost no commercial sales history, posts net losses, and held only about $14.0 million in cash at June 30, 2026 (against about $16.3 million of debt) and ongoing burn, so it relies on equity, warrants, and debt to operate. Most of its revenue is reimbursed government research, which can drop when a contract phase ends, as it did in the first half of 2026. With roughly 32 million shares and a tiny, volatile market cap, the stock can move sharply on news, which is typical of pre-commercial medical-AI companies.

Which ETFs or baskets include MDAI?

+

As a very small medical-AI company, MDAI is rarely a meaningful holding in major ETFs; when it appears, it is usually a tiny weight in small-cap or thematic funds, and holdings shift as funds rebalance, so check a specific ETF's current holdings with its provider. In Walnut you can hold MDAI as one constituent of a thematic basket, for example an AI-in-healthcare or speculative medical-technology theme, sized alongside other names to manage its single-stock risk.

Guides that feature MDAI

MDAI is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Spectral AI, Inc.'s investor relations page or your broker before making investment decisions.